23andMe Reports FY2023 First Quarter Financial Results
23andMe Holding Co. (ME)
Company Research
Source: GlobeNewswire
First quarter revenue grew 9% to $64.5 millionConsumer revenue grew 17% year over year due to the addition of telehealth revenueOn track to achieve FY2023 financial guidance SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the first quarter (“Q1”) of its fiscal year 2023 (“FY2023”), which ended June 30, 2022. 23andMe is the only company with multiple FDA authorizations for over-the-counter genetic health risk reports, and in particular the only company FDA authorized to provide, without physician involvement, genetic cancer risk reports and medication insights on how individuals may process certain commonly prescribed medications based on their genetics. The Company has also created the world’s largest crowdsourced platform for genetic research, which
Show less
Read more
Impact Snapshot
Event Time:
ME
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ME alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ME alerts
High impacting 23andMe Holding Co. news events
Weekly update
A roundup of the hottest topics
ME
News
- 23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- 23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire
- 23andMe announces CEO’s intention to pursue a potential take-privateGlobeNewswire
- Can 23andMe Holding (NASDAQ:ME) Afford To Invest In Growth? [Yahoo! Finance]Yahoo! Finance
- 23andMe Holding Co. (NASDAQ: ME) had its price target lowered by analysts at Citigroup Inc. from $0.85 to $0.47. They now have a "neutral" rating on the stock.MarketBeat
ME
Sec Filings
- 4/19/24 - Form 4
- 4/18/24 - Form 8-K
- 4/17/24 - Form SC
- ME's page on the SEC website